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OBJECTIVE—Increased availability of fatty acids is impor-
tant for accumulation of intracellular lipids and development
of insulin resistance in human myotubes. It is unknown
whether different types of fatty acids like eicosapentaenoic
acid (EPA) or tetradecylthioacetic acid (TTA) inﬂuence these
processes.
RESEARCH DESIGN AND METHODS—We examined fatty
acid and glucose metabolism and gene expression in cultured
human skeletal muscle cells from control and type 2 diabetic
individuals after 4 days of preincubation with EPA or TTA.
RESULTS—Type 2 diabetes myotubes exhibited reduced for-
mation of CO2 from palmitic acid (PA), whereas release of
-oxidation products was unchanged at baseline but signiﬁ-
cantly increased with respect to control myotubes after pre-
incubation with TTA and EPA. Preincubation with TTA
enhanced both complete (CO2) and -oxidation of palmitic
acid, whereas EPA increased only -oxidation signiﬁcantly.
EPA markedly enhanced triacylglycerol (TAG) accumulation
in myotubes, more pronounced in type 2 diabetes cells. TAG
accumulation and fatty acid oxidation were inversely corre-
lated only after EPA preincubation, and total level of acyl-CoA
was reduced. Glucose oxidation (CO2 formation) was en-
hanced and lactate production decreased after chronic expo-
sure to EPA and TTA, whereas glucose uptake and storage
were unchanged. EPA and especially TTA increased the
expression of genes involved in fatty acid uptake, activation,
accumulation, and oxidation.
CONCLUSIONS—Our results suggest that 1) mitochondrial
dysfunction in diabetic myotubes is caused by disturbances
downstream of fatty acid -oxidation; 2) EPA promoted accu-
mulation of TAG, enhanced -oxidation, and increased glucose
oxidation; and 3) TTA improved complete palmitic acid oxida-
tion in diabetic myotubes, opposed increased lipid accumulation,
and increased glucose oxidation. Diabetes 58:527–535, 2009
T
ype 2 diabetes is characterized by hyperglyce-
mia, reduced ability to oxidize fat, and accumu-
lation of triacylglycerol (TAG) in skeletal muscle
ﬁbers. The increased deposition of intramyocel-
lular TAG (imTAG) has received special interest, because
several studies have demonstrated a positive association
between insulin resistance and imTAG storage (1,2). Ac-
cumulation of imTAG depends on the availability and
uptake of fatty acids, the rate of fatty acid oxidation, and
the rate of synthesis and hydrolysis of TAG. Increased
availability of plasma free fatty acid (FFA) during lipid infusion
or high-fat feeding is associated with development of
insulin resistance and accumulation of imTAG in vivo (3).
Moreover, studies have shown impaired capacity for fatty
acid oxidation in skeletal muscle from insulin-resistant/
type 2 diabetic individuals (4,5), and reduced mitochon-
drial fatty acid oxidation in skeletal muscle and myotubes
is associated with increased deposition of imTAG (6–8).
Fatty acids may promote insulin resistance via intracellu-
lar intermediates such as acyl-CoA, diacylglycerol (DAG),
and ceramides, interfering with insulin signaling and glu-
cose metabolism (9).
Previous studies have demonstrated positive effects on
skeletal muscle insulin sensitivity of mono- and polyunsat-
urated fatty acids (PUFAs) compared with saturated fatty
acids (10–12). Very long–chain -3 fatty acids, including
eicosapentaenoic acid (EPA), may protect against skeletal
muscle insulin resistance caused by high-fat feeding in
vivo (1,13). PUFAs may also promote increased TAG
accumulation without impairing insulin-stimulated glu-
cose uptake in myotubes (10,11). The sulfur-substituted
fatty acid analog tetradecylthioacetic acid (TTA) is a
pan–peroxisome proliferator–activated receptor (pan-
PPAR) activator that reduces plasma lipids and enhances
hepatic fatty acid oxidation in rodents (14). Dual and
pan-PPAR agonists are currently being developed for
treatment of type 2 diabetes (15), and TTA has been shown
to improve glucose metabolism in insulin-resistant rats
(16) and to stimulate mitochondrial proliferation in rat
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DIABETES, VOL. 58, MARCH 2009 527skeletal muscle (17). We have recently demonstrated that
TTA may increase fatty acid oxidation in human myotubes
similar to the PPAR-speciﬁc agonist GW501516 (18).
Skeletal muscle metabolism is inﬂuenced by physical
activity, hormonal status, and muscle ﬁber type, rendering
it difﬁcult to determine the impact of EPA and TTA on
basal and insulin-stimulated intermediary metabolism.
Cultured human myotubes display the morphological, met-
abolic, and biochemical properties of adult skeletal mus-
cle (19) and offer a unique model to distinguish between
genetic and environmental factors in the etiology of insulin
resistance (20). We and others have reported several
potential intrinsic deﬁciencies in myotubes from individu-
als with type 2 diabetes, including lower basal palmitate
oxidation (21) and impaired insulin-stimulated glucose
metabolism (20,22). It is unknown whether EPA or TTA
may improve insulin resistance or other characteristics of
type 2 diabetes, such as decreased lipid oxidation in
myotubes.
To identify the potential effects of EPA and TTA on the
intermediary energy metabolism and insulin resistance,
we compared the effect of TTA, EPA, and oleic acid in
myotubes established from obese individuals with type 2
diabetes and obese healthy subjects.
RESEARCH DESIGN AND METHODS
Dulbecco’s modiﬁed Eagle’s medium (DMEM)-Glutamax, FCS, Ultroser G,
penicillin-streptomycin-amphotericin B, and trypsin-EDTA were obtained
from Gibco, Invitrogen (Paisley, U.K.). 2-[
3H(G)]deoxy-D-glucose (6.00 Ci/
mmol) and D-[
14C(U)]glucose (5 mCi/mmol) were purchased from
PerkinElmer, NEN (Boston, MA). [1-
14C]acetate (55 mCi/mmol), [1-
14C]PA (55
mCi/mmol), and D-[1-
14C]glucose (55 mCi/mmol) were obtained from Ameri-
can Radiolabeled Chemicals (St. Louis, MO). Palmitic acid, oleic acid, BSA
(essentially fatty acid free), cytochalasin B, and extracellular matrix gel were
purchased from Sigma-Aldrich (St. Louis, MO). Insulin Actrapid was from
Novo-Nordisk (Bagsvaerd, Denmark). Agilent Total RNA Isolation Mini kit
was purchased from Matriks (Oslo). The primers, SYBR Green and TaqMan
reverse-transcription reagents kit were obtained from Applied Biosystems
(Warrington, U.K.), and the protein assay kit was purchased from BioRad
(Copenhagen). EPA was purchased from NU-Chek-Prep, Ida kjemi (Ås,
Norway). TTA and [1-
14C]TTA were provided by R.K.B.
Biopsies. Skeletal muscle biopsies were obtained from eight obese type 2
diabetic patients (49.2  1.8 years) and eight obese control subjects (50.3 
1.8 years) taken from musculus vastus lateralis in the fasted state by needle
biopsy under local anesthesia. Only sedentary subjects were recruited.
Diabetic individuals were treated either with diet alone or in combination with
sulfonylurea, metformin, or insulin, which was withdrawn 1 week before
taking the biopsies. The patients had no diabetic complications apart from
simple retinopathy. The control subjects had normal glucose tolerance and no
family history of type 2 diabetes. The groups were matched with respect to age
and BMI but differed by fasting plasma glucose concentrations (5.5  0.2 vs.
10.4  0.7 mmol/l, P  0.001, t test), fasting serum insulin levels (50.5  5.6 vs.
96.1  12.5 pmol/l, P  0.05), glucose disappearance rate during euglycemic-
hyperinsulinemic clamp (280.0  34.8 vs. 121.1  23.2 mg  min
1  m
2, P 
0.001), and A1C (5.4  0.1 vs. 7.6  0.6%, P  0.05). All subjects gave written
informed consent, and the local ethics committee of Funen and Vejle County
approved the study.
Cell culture and fatty acid incubation. Myotubes were established from
satellite cells (19). Human myoblasts from control and type 2 diabetic subjects
were differentiated to myotubes at a physiological concentration of insulin (25
pmol/l) and glucose (5.5 mmol/l) for 4 days. Myotubes were then exposed to
BSA (40 mol/l), oleic acid (100 mol/l), TTA (100 mol/l), or EPA (100
mol/l) for another 4 days. Stock solutions of fatty acid sodium salts (6
mmol/l) and BSA (2.4 mmol/l) were heated to 45°C and rapidly mixed (molar
ratio of 2.5:1). Only optically clear solutions were used. There were no
differences between the myotubes after preincubation with fatty acids as
evaluated by microscopic inspection searching for ﬂoating cells or cells with
lipid droplets. The myotubes had similar protein content independent of
incubation medium.
Palmitic acid uptake and distribution of radiolabel in lipids
Palmitic acid uptake. Myotubes were incubated in DMEM supplemented
with 0.24 mmol/l BSA, 0.5 mmol/l L-carnitine, 20 mmol/l HEPES, [1-
14C]PA (0.5
Ci/ml, 0.6 mmol/l), and 25 pmol/l or 1.0 mol/l insulin for 4 h, to study basal
and insulin-mediated uptake and lipid distribution of palmitate.
De novo lipid synthesis. Myotubes preincubated with fatty acids were
further incubated4hi nmedium containing [1-
14C]acetate (3–4 Ci/ml, 100
mol/l). After incubation, myotubes were placed on ice, washed three times
with 1 ml PBS, scraped twice with 250 l distilled water, and homogenized.
The cell homogenates were assayed for protein and extracted for lipids, and
the radiolabeled lipids were separated by thin-layer chromatography (21) and
quantiﬁed by liquid scintillation. Total lipid uptake is the sum of oxidation
and storage products.
Measures of fatty acid oxidation
Acid-soluble metabolites. Myotubes were incubated in DMEM supple-
mented with 0.24 mmol/l BSA, 0.5 mmol/l L-carnitine, [1-
14C]PA (0.5 Ci/ml, 0.6
mmol/l), and 25 pmol/l or 1.0 mol/l insulin for4ht ostudy cellular release of
excess
14C–palmitic acid–derived acid-soluble metabolites (ASMs) to the
media. The incubation media were transferred to new tubes and assayed for
labeled ASMs, which mainly are byproducts of -oxidation remaining in
solution after precipitation of the radiolabeled fatty acid with perchloric acid
(PCA) (23).
CO2 and total oxidation. Myotubes were incubated in DMEM supple-
mented with 0.24 mmol/l BSA, 0.5 mmol/l L-carnitine, 20 mmol/l HEPES,
[1-
14C]PA (0.5 Ci/ml, 0.6 mmol/l), and 25 pmol/l insulin for4ht ostudy CO2
formation (21). PCA was added to the cells to measure both intra- and
extracellular (total) ASMs from palmitic acid. Thus, total palmitic acid
oxidation is the sum of CO2 and total ASMs.
Glucose metabolism. Glucose uptake, glycogen synthesis, and glucose
oxidation were determined as previously described (7).
RNA isolation and real-time RT-PCR. Myotubes were washed and centri-
fuged to a pellet before total RNA was isolated by Total RNA Isolation Mini kit
(Agilent), according to the supplier protocol. Total RNA (0.05 g/l) was
reversely transcribed with a TaqMan reverse-transcription reagents kit (7).
Quantitative RT-PCR was performed using an ABI PRISM 7000 Detection
System. DNA expression was determined by SYBR Green (7), and primers for
uncoupling protein 2 (UCP2), fatty acid translocase (CD36/FAT), carnitine
palmitoyl transferase (CPT)-1a, CPT2, fatty acid binding protein 3 (FABP3),
long-chain acyl-coenzyme A synthetase 1 (ACSL1), ACSL3, mitochondrial
trifunctional protein -subunit (HADHB), acyl-coenzyme A dehydrogenase
medium-chain (ACADM), DGAT1, DGAT2, hexokinase II (HKII), GLUT1,
GLUT4, actin- (ACT), and ribosomal protein, large, P0 (RPLP0) (supple-
mental Table 1, available in an online appendix at http://dx.doi.org/10.2337/
db08-1043) were designed using Primer Express (Applied Biosystems). In
addition, expression of CPT1b, citrate synthase (CS), malate dehydrogenase 2
(MDH2), ACC2, UCP3, stearoyl-coenzyme A desaturase 1 (SCD1), PGC1a,
ACTB, and RPLP0 (supplemental Table 1) were analyzed with the inventoried
TaqMan gene expression assays of Applied Biosystems on a 7900HT Fast
Real-Time PCR system with 96-well block module following standard proto-
cols. The transcription levels were normalized to ACTB and RPLP0.
Analysis of acyl-CoA fractions. Cells were harvested by centrifugation and
washed twice with 10 mmol/l PCA and stored at 80°C until long-chain fatty
acyl-CoA (LCFA-CoA) extraction. Heptadecanoyl-CoA (33 pmol) and H2O
were added to a ﬁnal volume of 800 l before addition of 3 ml chloroform:
methanol (2:1). Cells were then homogenized with an Ultraturrax homoge-
nizer. Chloroform (1 ml) and H2O (1 ml) were added and vortexed vigorously.
After centrifugation (3,000 rpm/10 min/4°C), the interphase was recovered and
dried under a stream of N2. The LCFA-CoAs were further extracted and
derivatized to ﬂuorescent acyl etheno-CoA esters using 0.5 mol/l chloroacet-
aldehyde, 0.5% SDS, and 0.15 mol/l citrate, pH 4 (200 l), and then separated
and analyzed by reverse-phase chromatography (24). Peak areas were inte-
grated using Chromeleonc version 6.50 (Dionex) and quantiﬁed relative to the
internal heptadecanoyl-CoA standard. Identiﬁcation of individual LCFA-CoA
was performed using standard LCFA-CoA mixtures. The detection level of our
methods was 0.5 pmol/l.
Scintillation proximity assay. We applied this method because it provides
accurate and reproducible cell data with limited use of resources for quite
extensive analyses (25). In short, radiolabeled substrates taken up and
accumulated by adherent cells are concentrated close to the scintillator
embedded in the plastic bottom of each well and thus provide a stronger
signal than the radiolabel dissolved in the medium alone (25). Myotubes were
preincubated with 100 mol/l oleic acid for 4 days with addition of 100 mol/l
TTA the last 24 h. Then myotubes were washed with PBS, medium containing
[1-
14C]PA (1 Ci/ml, 100 mol/l) was added, and myotubes were incubated up
to 4 h. Fatty acid was bound to BSA at a ratio of 2.5:1.
Statistical analysis. The effect of group and incubations was evaluated by
linear mixed models analysis in SPSS (v12.0.1), monitoring group and treat-
ment effects based on all available data from each experiment and taking into
account the correlation between measurements/myotubes from the same
subjects. Some acyl-CoA values were below detection limit and were assigned
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statistical analyses (Mann-Whitney and Wilcoxon’s signed-rank test) were
performed on the acyl-CoA data for evaluation of group and treatment
differences, respectively. A P value 0.05 was considered signiﬁcant.
RESULTS
Effect of fatty acids on uptake and oxidation of fatty
acids. We observed enhanced uptake of
14C–palmitic acid
in cultured myotubes from controls and type 2 diabetic
subjects after 4 days of preincubation with oleic acid, EPA,
or TTA (Fig. 1A), showing that fatty acid availability is
important for cellular lipid uptake. By adding 1 mol/l
insulin acutely,
14C–palmitic acid accumulation was fur-
ther enhanced by 15–30% (data not shown; P  0.05).
There was an allover signiﬁcant 20% reduction in
14C–
palmitic acid–derived CO2 released from type 2 diabetes
vs. control myotubes (Fig. 1B), indicating that type 2
diabetes cells exhibit reduced complete palmitic acid
oxidation. However, after incubation with TTA, control
and type 2 diabetes myotubes showed enhanced
14CO2
production from
14C–palmitic acid compared with base-
line or preincubation with oleic acid (Fig. 1B), suggesting
that TTA may improve mitochondrial fatty acid oxidation.
The percentage of palmitic acid that was oxidized com-
pletely to CO2 compared with total oxidation [sum of
complete (CO2) plus incomplete fatty acid oxidation
(ASMs)] was lower in type 2 diabetes myotubes, especially
after preincubation with TTA (Fig. 1C). Preincubation with
EPA and TTA enhanced
14C–palmitic acid–derived ASMs
recovered in the media, and the response was signiﬁcantly
stronger in type 2 diabetes myotubes (EPA 125% and TTA
128%) compared with control myotubes (EPA 45% and
TTA 47%; Fig. 2A). In the presence of insulin, preincuba-
tion with EPA, TTA, and oleic acid enhanced ASM release,
with a stronger allover response in type 2 diabetes com-
pared with control myotubes (Fig. 2B). We also observed
similar effects of EPA and TTA on ASMs derived from
14C–oleic acid, with signiﬁcantly stronger release from
type 2 diabetes than control myotubes in the presence of
insulin (data not shown).
Accumulation of TAG. Preincubation of myotubes with
oleic acid and EPA enhanced
14C–palmitic acid accumula-
tion into lipids compared with baseline by 23–32% and
29–53%, respectively (results not shown; P  0.05). The
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FIG. 1. Palmitate uptake and oxidation. Differentiated myotubes from type 2 diabetic or control subjects were preincubated with 40 mol/l BSA,
100 mol/l oleic acid, 100 mol/l TTA, or 100 mol/l EPA for 4 days and incubated with 0.6 mmol/l [1-
14C]PA for 4 h. The panels show palmitate
uptake, which is the sum of total recovered CO2, ASMs, and total lipids (A); oxidation to CO2 (B); CO2 from palmitic acid as percentage of total
oxidation (C). Results present means  SE (n  8). a, P < 0.05 vs. baseline; b, P < 0.05 vs. oleic acid; c, P < 0.05 vs. EPA; #P < 0.05 vs. ObControl,
analyzed by linear mixed models statistics (SPSS), which also calculated the allover results based on all available data. T2D, type 2 diabetes.
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FIG. 2. Palmitate-derived ASMs release to the medium. Differentiated
myotubes from type 2 diabetes or control subjects were preincubated
with fatty acids as described in Fig. 1 and then acutely incubated with
0.6 mmol/l [1-
14C]PA  1 mol/l insulin for 4 h. The panels show ASMs
released from the cells, derived from
14C–palmitic acid without (A) and
with (B)1mol/l insulin. Results represent means  SE (n  6–7). a,
P < 0.05 vs. baseline; b, P < 0.05 vs. oleic acid; #P < 0.05 vs. ObControl,
analyzed by linear mixed models statistics (SPSS), which also calcu-
lated the allover results based on all available data.
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strong increment in TAG accumulation after preincubation
with oleic acid (7.4 and 7.9 nmol/mg cell protein, control,
and type 2 diabetes, respectively) and EPA (10.9 and 17.5
nmol/mg cell protein, control, and type 2 diabetes, respec-
tively) compared with baseline (results not shown; P 
0.05). The relative increase in TAG accumulation was
signiﬁcantly higher in type 2 diabetes than control myo-
tubes after preincubation with EPA (Fig. 3A). Preincuba-
tion with TTA did not increase total
14C–palmitic acid lipid
accumulation, although radiolabeled TAG was slightly
increased compared with baseline but reduced compared
with oleic acid and EPA (Fig. 3A). Similar effects of oleic
acid, EPA, and TTA on lipid synthesis were observed using
14C–oleic acid (data not shown). Moreover, preincubation
with EPA caused a negative correlation between relative
change in total oxidation and TAG synthesis from
14C–
palmitic acid (r  0.69, P  0.005) (Fig. 3B), but not with
oleic acid or TTA (results not shown).
Gene expression related to mitochondrial function
and lipid metabolism. There were no differences be-
tween the two groups in expression of several genes
important for mitochondrial function and fatty acid me-
tabolism (Table 1). Preincubation with fatty acids in-
creased the expression of CPT1-/ (1.5- to 2-fold) and
HADHB (30%). However, UCP2 and -3 were moderately
increased with respect to baseline by 43 and 24%, respec-
tively, only after preincubation with TTA.
Expression of CD36/FAT, ACSL, and FABP3 was in-
creased after preincubation with TTA more so than oleic
acid and EPA (Table 1). Preincubation with TTA also
promoted a 2.5-fold induction in SCD1 compared with the
other fatty acids (Table 1). DAG acyltransferase 2
(DGAT2), responsible for the ﬁnal step in TAG synthesis,
was increased similarly by all fatty acids in control myo-
tubes, whereas type 2 diabetes myotubes displayed a
reduced response, especially during incubation with TTA
(Fig. 4A). The nuclear transcription factor PPAR	 coacti-
vator 
 (PGC1) had a similar expression pattern to
DGAT2, with enhanced expression after fatty acid prein-
cubation in control cells and reduced response in type 2
diabetes myotubes (Fig. 4B).
Acyl-CoA fractions. Total acyl-CoA was increased rela-
tive to baseline after preincubation with TTA, whereas
preincubation with EPA reduced acyl-CoA by 40% in
type 2 diabetes myotubes but signiﬁcantly less in control
cells (Fig. 5A). Preincubation with EPA reduced C18:1-
CoA by an average of 61% (not shown; P  0.05) and
C16:0-CoA by 46–55% (Fig. 5B) relative to baseline,
whereas C16:1-CoA was markedly increased (Fig. 5C).
EPA also substantially reduced the level of C18:2-CoA
relative to baseline in type 2 diabetes myotubes, to a level
signiﬁcantly lower than in control myotubes (Fig. 5D).
Preincubation with oleic acid reduced C16:0-CoA by 71–
82% (Fig. 5B) and increased C18:1-CoA by an average of
75% (not shown; P  0.05) relative to baseline. TTA-CoA
and C16:0-CoA had similar retention times and therefore
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TABLE 1
Gene expression relative to baseline
Baseline
(Ct no.) Oleic acid EPA TTA
CPT1 1.00 (27) 2.25  0.09
a 2.24  0.11
a 2.23  0.11
a
CPT1 1.00 (33) 1.71  0.10
a 1.42  0.07
ab 1.78  0.15
ac
CPT2 1.00 (30) 1.08  0.03
a 1.04  0.03 1.05  0.03
ACADM 1.00 (28) 1.08  0.08 1.05  0.08 0.97  0.06
HADHB 1.00 (24) 1.32  0.06
a 1.38  0.06
a 1.31  0.06
a
CS 1.00 (26) 1.10  0.04
a 0.99  0.03
b 1.12  0.04
ac
MDH2 1.00 (25) 1.04  0.02 1.00  0.02
b 1.04  0.02
a
UCP2 1.00 (28) 1.14  0.10 0.84  0.06
ab 1.43  0.08
abc
UCP3 1.00 (34) 1.11  0.07 0.96  0.06
b 1.24  0.07
ac
CD36/FAT 1.00 (29) 2.05  0.11
a 2.01  0.10
a 4.41  0.32
abc
ACSL1 1.00 (25) 1.25  0.04
a 1.21  0.05
a 1.13  0.04
ab
ACSL3 1.00 (24) 1.51  0.11
a 1.63  0.09
a 2.01  0.13
abc
FABP3 1.00 (25) 1.33  0.06
a 1.56  0.06
ab 2.75  0.26
abc
SCD1 1.00 (24) 0.88  0.07 1.05  0.08
b 2.50  0.26
abc
DGAT1 1.00 (34) 1.00  0.13 1.29  0.21 1.26  0.11
a
Data are means  SE (n  16). Individual results were normalized to baseline (set to 1; average baseline Ct numbers for the investigated
genes are shown in brackets, giving an impression of relative expression levels).
aP  0.05 vs. baseline;
bP  0.05 vs. oleic acid;
cP  0.05
vs. EPA analyzed by linear mixed models statistics (SPSS).
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530 DIABETES, VOL. 58, MARCH 2009appeared in the same peak on the chromatogram. The
relative increase in acyl-CoA after preincubation with TTA
(Fig. 5A) could be ascribed to a marked increase in the
combined TTA/C16:0-CoA peak compared with C16:0-CoA
at baseline (Fig. 5B). Interestingly, C20:4-CoA was de-
creased in type 2 diabetes compared with control myo-
tubes after fatty acid preincubations and signiﬁcantly after
TTA (Fig. 5E).
Glucose metabolism. Diabetic myotubes displayed an
allover (basal and insulin-stimulated) 10% decreased glu-
cose oxidation compared with control cells (results not
shown; P  0.05). Basal and insulin-mediated glucose
oxidation was enhanced after preincubation with EPA
(24%) and TTA (28%) in myotubes from both groups
(results not shown, P  0.05). Glucose uptake and glyco-
gen synthesis, however, were mostly unaffected by prein-
cubations with fatty acids (data not shown). Thus,
preincubation with EPA and TTA may have reduced
nonoxidized glucose metabolites like lactate and pyruvate,
accounting for the increased glucose oxidation. Moreover,
the mRNA expression of GLUT4, GLUT1, and HKII were
unchanged after fatty acid preincubations (results not
shown).
TTA inhibits the oleic acid–mediated increase of
cell-associated
14C–palmitic acid. We monitored incor-
poration of
14C-TTA into complex cellular lipids and found
that only a minimal amount was recovered in the TAG
fraction, whereas most was found in phospholipids (not
shown). De novo synthesis of fatty acids from
14C-acetate
was similar after 4 days of preincubation of myotubes with
TTA compared with baseline (Fig. 6A), but the ratio
between radioactivity recovered in DAG and TAG was
sevenfold higher after TTA (Fig. 6A). To further elucidate
the impact of TTA on cellular fatty acid accumulation, we
monitored the time course for cell-associated
14C–palmitic
acid by scintillation proximity assay (SPA). As expected, 4
days of preincubation with oleic acid caused enhanced
cell-associated
14C–palmitic acid (Fig. 6B). TTA itself
caused no change compared with baseline, and addition of
TTA for the last 24 h of the oleic acid preincubation period
was sufﬁcient to inhibit the oleic acid–mediated increase
in cell-associated
14C–palmitic acid (Fig. 6B). Together,
these data suggest that TTA or TTA-CoA may reduce fatty
acid–stimulated TAG synthesis, possibly by inhibiting
DGAT activity as also suggested previously in rat livers
(26).
DISCUSSION
Cultured human myotubes is the most similar cell system
to intact skeletal muscle that can be modulated ex vivo.
Compared with rodent models, they express the right
genetic background and the speciﬁc skeletal muscle phe-
notype. The extracellular environment can be controlled
precisely and kept relatively constant over time, without
interference by systemic homeostatic compensatory
mechanisms. We and others have reported several poten-
tial intrinsic deﬁciencies in myotubes from individuals
with type 2 diabetes (20–22). These differences appear
most obvious when comparing myotubes established from
lean with obese type 2 diabetic subjects but are not always
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DIABETES, VOL. 58, MARCH 2009 531signiﬁcant when comparing obese with obese type 2
diabetes (27). We studied the effects of EPA and TTA on
the intermediary energy metabolism and insulin resistance
in myotubes established from obese subjects with type 2
diabetes and obese healthy subjects. We have previously
demonstrated reduced capacity for complete oxidation of
labeled palmitic acid to CO2 in myotubes from obese type
2 diabetic subjects compared with obese control myotubes
(21), and this dysfunction was reproduced in our present
study. Here, we observed that CO2 production from la-
beled palmitic acid was reduced for diabetic myotubes
(Fig. 7A vs. B). Furthermore, the release of fatty acid
-oxidation products (ASMs) was increased by type 2
diabetes compared with control myotubes after preincu-
bation with fatty acids (Fig. 7C vs. D). Our data suggest
that mitochondrial dysfunction in type 2 diabetes myo-
tubes is probably caused by disturbances downstream of
fatty acid -oxidation leading to excess production and
release of ASMs during increased inﬂux and/or -oxidation
of fatty acids. In support for this, several studies have
suggested a mitochondrial dysfunction in the etiology of
insulin resistance and type 2 diabetes (4,6,28). Moreover,
increased levels of -oxidation products have been found
in both murine skeletal muscle and plasma, probably
reﬂecting mitochondrial overload due to excess availabil-
ity of fatty acids (29,30).
Excess FFA taken up by myotubes may either be
oxidized or stored as TAG. PGC1 is an important regu-
lator of muscle oxidative capacity, mitochondrial content,
and ﬁber type (31,32), and insulin resistance may be
negatively associated with PGC1 expression in skeletal
muscle (33,34). In the present study, gene expression of
PGC1 was increased in response to fatty acids, but the
relative response was blunted in diabetic myotubes com-
pared with control cells. In C2C12 myotubes, PGC1
expression was enhanced after 4 h but reduced after 16 h
of incubation with palmitic acid (35), whereas unsaturated
fatty acids like oleic acid and linoleic acid enhanced
PGC1 expression in human myotubes (36). Our data
suggest that the reduced capacity for complete mitochon-
drial fatty acid oxidation observed for type 2 diabetes
myotubes might be related to suboptimal responses in
expression of PGC1, e.g., when the myotubes are ex-
posed to fatty acids. DGAT2, which is involved in TAG
formation (37), showed a similar expression pattern to
PGC1, and the expression of these genes correlated well
(r  0.81, P  0.0001). Reduced DGAT2 gene expression
after preincubation with fatty acids in diabetic cells,
together with impaired complete fatty acid oxidation, may
contribute to enhanced levels of potentially lipotoxic
intracellular fatty acid intermediates and might play a role
in lipid-induced insulin resistance.
Preincubation of myotubes with EPA led to increased
production of ASMs, whereas TTA increased both ASMs
and CO2 production (Fig. 7C and D). Increased formation
of -oxidation intermediates may cause mitochondrial
stress and induce skeletal muscle insulin resistance
(30,38). However, we did not observe any detrimental
effects of chronic preincubation with either EPA or TTA
on insulin-stimulated glucose metabolism in human myo-
tubes. This does not exclude any such link, because we did
not coincubate with fatty acids during the glucose exper-
iments that might be a prerequisite for negative effects to
occur. Nevertheless, Power et al. (39) showed that supple-
mentation with L-carnitine could ameliorate rather than
worsen insulin resistance in mice, despite increased levels
of -oxidation products in plasma and skeletal muscle.
Furthermore, preincubation with EPA and TTA increased
glucose oxidation, suggesting improved instead of reduced
capacity for glucose handling (Fig. 7C and D).
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fatty acids enhanced
14C–palmitic acid uptake in line with
previous observations (8,10), and EPA was more effective
than oleic acid (Fig. 7C and D). Preincubation with oleic
acid, and especially EPA, also promoted increased incor-
poration of
14C–palmitic acid into TAG, and the response
to EPA was more pronounced in diabetic myotubes (Fig.
7C vs. D). We observed a negative correlation between
total fatty acid oxidation and TAG synthesis in the pres-
ence of EPA, suggesting that EPA may redirect excess
fatty acids into TAG. Storage of excess fatty acids such as
TAG may protect against cell damage due to neutralization
of lipotoxic intermediates (40,41). Furthermore, EPA re-
duced the total amount of acyl-CoA, in particular C18:2-
CoA, and the reduction was greatest for diabetic
myotubes. Increased levels of acyl-CoA and especially
C18:2-CoA have been associated with insulin resistance
(42,43). Moreover, EPA markedly increased the level of
C16:1-CoA, which has recently been shown to function as
a lipokine improving peripheral insulin action (44) and
glucose metabolism in L6 rat myotubes (45). In addition,
incubation of myotubes from normal lean subjects with
EPA improved glucose uptake, despite an increased incor-
poration of
14C–oleic acid into TAG (10). In rats, EPA also
improved insulin resistance while increasing imTAG levels
(46).
Preincubation with TTA increased complete oxidation
of
14C–palmitic acid to CO2 to a similar degree in control
and diabetic myotubes. Thus, TTA “restored” complete
palmitic acid oxidation in diabetic cells to baseline level of
control myotubes (Fig. 7A and B vs. D). The uptake of
palmitic acid was increased after preincubation with TTA
but did not lead to similar accumulation of
14C–palmitic
acid into TAG compared with preincubation with oleic
acid or EPA. The reduced TAG accumulation may reﬂect
enhanced fatty acid oxidation, and we have data showing
increased TAG accumulation from
14C–palmitic acid after
TTA preincubation when myotubes were acutely coincu-
bated with the CPT1 inhibitor etomoxir (A.J.W., A.C.R.,
unpublished observations). Alternatively, TTA-CoA may
inhibit DGAT activity (26), as also suggested by the
markedly increased cellular DAG-to-TAG recovery ratio of
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lipid synthesis. Furthermore, we observed that
14C-TTA
itself could not be efﬁciently incorporated into TAG in
human myotubes and that coincubation with TTA pre-
vented the oleic acid–induced increase in cell-associated
14C–palmitic acid. Moreover, myotubes preincubated with
TTA had enhanced levels of acyl-CoA and TTA-CoA prob-
ably accounted for most of the difference because 3-thia
fatty acids cannot undergo -oxidation (14). However,
preincubation of myotubes with TTA neither impaired
insulin-stimulated glucose uptake nor glycogen synthesis,
whereas glucose oxidation was increased in cells from
both donor groups (Fig. 7C and D).
TTA may enhance mitochondrial proliferation in skele-
tal muscle (17), and activation of PPAR nuclear receptors
probably mediates much of the effects of TTA on gene
expression (16,18,26). Because there were no differences
in induction of CPT1 expression after preincubation with
TTA relative to oleic acid and EPA, the enhanced -oxi-
dation after TTA may be explained by the twofold higher
induction of CD36/FAT expression. CD36 may facilitate
fatty acid transport across the plasma membrane in re-
sponse to contraction and insulin (47), but CD36 may also
reside on the outer mitochondrial membrane (48) in
colocalization with CPT1 to facilitate mitochondrial fatty
acid inﬂux (48,49). In rats, the PPAR	 agonist rosiglitazone
increased skeletal muscle fatty acid oxidation and mito-
chondrial CD36 amount, but not CPT1 protein expression
or activity (49), which is in line with our observations. Part
of the increased oxidation of
14C–palmitic acid to CO2
after preincubation with TTA may be related to the in-
creased UCP2 expression and mitochondrial uncoupling
(50). Thus, preincubation with the synthetic fatty acid
analog TTA enhanced complete fatty acid and glucose
oxidation in diabetic myotubes and opposed the increased
lipid accumulation observed after preincubation with oleic
acid and especially EPA.
In summary, type 2 diabetes myotubes seem to have an
impaired mitochondrial capacity for fatty acid oxidation
and glucose (Fig. 7A vs. B), linked to defects downstream
of fatty acid -oxidation, leading to increased release of
ASMs during high fatty acid availability (Fig. 7C vs. D).
Reduced response of PGC
 to fatty acids in diabetic
myotubes may be associated with reduced mitochondrial
function and reduced DGAT activity, creating lipid inter-
mediates and consequently insulin resistance. TTA and
EPA might execute beneﬁcial effects by increasing com-
plete fatty acid oxidation and TAG formation, respectively
(Fig. 7C and D), thereby improving overall energy metab-
olism and fatty acid handling in type 2 diabetes skeletal
muscle.
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